In the BioHarmony Drug Report Database
Tenapanor
Ibsrela (tenapanor) is a small molecule pharmaceutical. Tenapanor was first approved as Ibsrela on 2019-09-12. It is used to treat irritable bowel syndrome in the USA. It is known to target sodium/hydrogen exchanger 3. Ibsrela’s patents are valid until 2030-05-02 (FDA).
Trade Name
|
Ibsrela |
|---|---|
Common Name
|
tenapanor |
ChEMBL ID
|
CHEMBL3304485 |
Indication
|
irritable bowel syndrome |
Drug Class
|
Sodium-hydrogen antiporter inhibitors |
Image (chem structure or protein)